Infinity Pharmaceuticals, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2010-12-14: Form 8-K; Period of report 2010-12-10; Description 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 1.01.
- 2010-12-01: Form 8-K; Period of report 2010-12-01; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2010-11-17: Form 8-K; Period of report 2010-11-17; Description 7.01 Regulation FD Disclosure; Details 7.01.
- 2010-11-09: Form 8-K; Period of report 2010-11-09; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2010-12-14 | 8-K | 2010-12-10 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 Entry into a Material Definitive Agreement. 5.02 (e) On December 10, 2010, the Compensation Committee of our Board of Directors awarded Steven H. Holtzman, founder and executive chair of our Board, a grant of 100,000 shares of our common stock and $400,000 in cash, in recognition of services rendered to our company. | d8k.htm |
| 2010-12-01 | 8-K | 2010-12-01 | 7.01 Regulation FD Disclosure | 7.01 From time to time, we intend to conduct meetings with third parties in which our current corporate slide presentation is presented. | d8k.htm |
| 2010-11-17 | 8-K | 2010-11-17 | 7.01 Regulation FD Disclosure | 7.01 From time to time, we intend to conduct meetings with third parties in which our current corporate slide presentation is presented. | d8k.htm |
| 2010-11-09 | 8-K | 2010-11-09 | 2.02 Results of Operations and Financial Condition | 2.02 On November 9, 2010, we issued a press release announcing our results for the quarter ended September 30, 2010 and will conduct a previously-announced, publicly-available conference call to discuss those results. | d8k.htm |
| 2010-11-08 | 8-K | 2010-11-03 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On November 3, 2010, Steven H. Holtzman, the current Executive Chair of our Board of Directors, provided notice that effective December 31, 2010 he will transition from Executive Chair to non-executive Chair of our Board of Directors. | d8k.htm |
| 2010-10-27 | 8-K | 2010-10-26 | 8.01 Other Events | 8.01 On October 26, 2010, we issued a press release announcing that Purdue Pharmaceutical Products L.P. and its independent associated company, Mundipharma International Corporation Ltd., exercised their right to assume worldwide development and commercialization activities for our fatty acid amide hydrolase program. | d8k.htm |
| 2010-10-12 | 8-K | 2010-10-10 | 8.01 Other Events | 8.01 On October 10, 2010, we issued a press release announcing Phase 1 data of IPI-926 in patients with advanced or metastatic solid tumors. | d8k.htm |
| 2010-09-15 | 8-K | 2010-09-15 | 7.01 Regulation FD Disclosure | 7.01 From time to time, we intend to conduct meetings with third parties in which our current corporate slide presentation is presented. | d8k.htm |
| 2010-08-04 | 8-K | 2010-08-04 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On August 4, 2010, we issued a press release announcing our results for the quarter ended June 30, 2010 and will conduct a previously-announced, publicly-available conference call to discuss those results. 7.01 From time to time, we intend to conduct meetings with third parties in which our current corporate slide presentation is presented. | d8k.htm |
| 2010-07-13 | 8-K | 2010-07-07 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 On July 7, 2010 Infinity Pharmaceuticals, Inc. (“Infinity”) entered a development and license agreement (the “Agreement”) with Intellikine, Inc. (“Intellikine”) to discover, develop and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of phosphoinositide-3-kinase (“PI3K”). 8.01 On July 8, 2010, Infinity issued a press release announcing the entry into a development and license agreement with Intellikine, Inc. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. | d8k.htm |
| 2010-06-04 | 8-K | 2010-06-04 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 From time to time, we intend to conduct meetings with third parties in which our current corporate slide presentation is presented. 8.01 On June 4, 2010, we issued a press release announcing results from our Phase 2 clinical trial of IPI-504 in patients with non-small cell lung cancer. | d8k.htm |
| 2010-05-28 | 8-K | 2010-05-25 | 1.01 Entry into a Material Definitive Agreement; 5.07 Submission of Matters to a Vote of Security Holders | 1.01 Entry into a Material Definitive Agreement. | d8k.htm |
| 2010-05-06 | 8-K | 2010-05-06 | 2.02 Results of Operations and Financial Condition | 2.02 On May 6, 2010, we issued a press release announcing our results for the quarter ended March 31, 2010 and will conduct a previously-announced, publicly-available conference call to discuss those results. | d8k.htm |
| 2010-02-10 | 8-K | 2010-02-10 | 2.02 Results of Operations and Financial Condition | 2.02 On February 10, 2010, we issued a press release announcing our results for the quarter and year ended December 31, 2009 and will conduct a previously-announced, publicly-available conference call to discuss those results. | d8k.htm |
| 2010-01-11 | 8-K | 2010-01-05 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure; 8.01 Other Events | 5.02 Additional information regarding the compensation of our directors and executive officers will be included in our proxy statement to be filed in connection with our annual meeting of stockholders to be held in May 2010. 7.01 From time to time, we intend to conduct meetings with third parties in which our current corporate slide presentation is presented. 8.01 On January 11, 2010, we issued a press release announcing our 2010 research and development and business goals. | d8k.htm |